The Economic Times

Biocon shares rise 2% after USFDA approval for Yesintek single-dose prefilled autoinjector

Biocon shares rose after its US subsidiary received supplemental FDA approval for Yesintek single-dose prefilled autoinjectors in two strengths. The approval expands Biocons US immunology portfolio, with Yesintek used to treat conditions including plaque psoriasis, psoriatic arthritis, Crohns disease and ulcerative colitis.